of Epithelial-Mesenchymal Transition Is Essential
for Squamous Cell Carcinoma Metastasis
Jeff H. Tsai,1Joana Liu Donaher,3Danielle A. Murphy,4Sandra Chau,1and Jing Yang1,2,*
1Department of Pharmacology
2Department of Pediatrics
University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093-0636, USA
3Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA
4The Sanford Burnham Medical Research Institute, La Jolla, CA 92037, USA
Epithelial-mesenchymal transition (EMT) is implicated in converting stationary epithelial tumor cells into
motile mesenchymal cells during metastasis. However, the involvement of EMT in metastasis is still contro-
versial, due to the lack of a mesenchymal phenotype in human carcinoma metastases. Using a spontaneous
squamous cell carcinoma mouse model, we show that activation of the EMT-inducing transcription factor
Twist1 is sufficient to promote carcinoma cells to undergo EMT and disseminate into blood circulation.
Importantly, in distant sites, turning off Twist1 to allow reversion of EMT is essential for disseminated tumor
cells to proliferate and form metastases. Our study demonstrates in vivo the requirement of ‘‘reversible EMT’’
in tumor metastasis and may resolve the controversy on the importance of EMT in carcinoma metastasis.
During metastasis, epithelial tumor cells invade surrounding
tion, and then establish secondary tumors in distant sites. A
developmental program termed epithelial-mesenchymal transi-
tion (EMT) has been implicated in giving rise to the dissemination
of single carcinoma cells. During EMT, stationary epithelial cells
lose their epithelial characteristics, including adherent junctions
and apical-basal polarity, and acquire a mesenchymal mor-
phology and the ability to migrate and invade (Hay, 1995).
Biochemically, cells switch off the expression of epithelial
markers, such as adherens junction proteins E-cadherin and
catenins, and turn on mesenchymal markers, including vimentin
and fibronectin. Studies using cell culture and tumor xenograft
models show that activation of EMT promotes carcinoma cells
to dissociate from each other and metastasize to distant organs
(Hay, 1995; Kalluri and Weinberg, 2009; Thiery, 2002, 2009).
However, the involvement of EMT in tumor metastasis in vivo
is still hotly debated (Garber, 2008; Ledford, 2011; Tarin et al.,
2005; Thompson et al., 2005). In human carcinoma, although
primary tumors show many morphological and molecular
features of EMT in subpopulations of invasive cells, distant
metastases present an epithelial morphology (Peinado et al.,
2007).This phenomenoncontradicts the assumptionthatactiva-
tion of EMT in tumor cells should result in metastases with
a mesenchymal phenotype, therefore casting doubts on the
occurrence of EMT during metastasis. This discrepancy could
be due to the interpretation of the EMT program as a permanent
nonreversible course during tumor metastasis. A reversible EMT
model has been proposed to explain this apparent paradox:
carcinoma cells undergo EMT to invade and disseminate from
the primary tumor; once reaching distant sites, tumor cells
need to revert to an epithelial identity to form macrometastases
(Thiery, 2002). However, this hypothesis has not been attested
EMT features are frequently observed in many types of primary human carcinoma, but not their corresponding metastases.
Our findings indicate that reversible EMT likely represents a key driving force in human carcinoma metastasis. Delayed
onset of metastasis following primary tumor removal is thought to be due to resurrection of latent carcinoma cells in distant
organs. Our study raises the possibility that tumor dormancy could be due to the inability of disseminated tumor cells to
revert EMT and proliferate. The dynamic involvement of EMT in metastasis cautions that therapies inhibiting EMT could
be counterproductive in preventing distant metastases when patients already present circulating tumor cells. Instead,
blocking EMT reversion may prevent dormant tumor cells from establishing metastases.
Cancer Cell 22, 725–736, December 11, 2012 ª2012 Elsevier Inc. 725
The EMT program is orchestrated through a network of tran-
scription factors, including Twist1 (Yang et al., 2004), Snail1/2
(Batlle et al., 2000; Cano et al., 2000; Hajra et al., 2002), Zeb1/2
(Comijn et al., 2001; Eger et al., 2005), and FOXC2 (Mani et al.,
2007). Our previous study found that Twist1 is a potent inducer
of EMT and invadopodia-mediated ECM degradation (Eckert
xenograft models, Twist1 expression can promote tumor metas-
tasis (Yang et al., 2004). Clinical studies have also associated
expression of Twist1 in primary tumors with disease aggressive-
ness and poor survival in many types of human cancers, such as
squamous cell carcinoma, breast cancer, prostate cancer, and
gastric cancer (Eckert et al., 2011; Kallergi et al., 2011; Peinado
et al., 2007; Watson et al., 2007).
Unlike human carcinoma metastases, most established meta-
type (Blick et al., 2008) and cannot be used to address the
dynamic EMT process during tumor metastasis in vivo. Recent
elegant studies using autochthonous mouse tumor models
observed the occurrence of EMT in primary carcinoma, but
how EMT spatiotemporally regulates metastasis has not been
investigated in these models (Hu ¨semann et al., 2008; Rhim
et al., 2012). The chemical carcinogenesis mouse skin model
has been shown to recapitulate the multistep process of human
carcinoma progression, including initiation, growth, invasion,
and metastasis (Kemp, 2005; Perez-Losada and Balmain,
2003). At the molecular and genetic levels, the skin carcinogen-
esis model shares strong similarities with a number of carcinoma
in humans, including activating mutations in Ras family mem-
bers, activation of PI3K- and Stat3-mediated signaling path-
ways, elevated expression of transforming growth factor b1
(TGFb1), and activation of the TGFb/Smad signaling pathways
and, at later stages, Trp53 mutations (DiGiovanni, 1992; Kemp,
2005). Importantly, like human squamous cell carcinoma, this
model develops distant metastases with an epithelial mor-
phology in lymph nodes and lungs (Han et al., 2005), making it
a suitable model to study the involvement of EMT in vivo.
Furthermore, extensive studies have shown that expression of
Twist1 in primary human squamous cell carcinoma, including
esophageal cancer (Sasaki et al., 2009; Xie et al., 2009; Yuen
et al., 2007) and head and neck cancer (Ou et al., 2008; Wushou
et al., 2012), correlates with distant metastasis and poor
prognosis. In this study, we investigate the importance of the
dynamic EMT process in metastasis in vivo using the skin carci-
Induction of Twist1 Promotes Invasive Carcinoma
Previous studies have demonstrated the necessary role of
Twist1 as an inducer of EMT. To understand the contribution of
Twist1 in metastatic carcinoma, we analyzed 99 primary human
carcinomas with patient-matched lymph node metastases for
Twist1 expression. Of the 20 cases with high Twist1 expression
in the primary tumor, we found 16 cases with over 50% drop in
Twist1 levels in the lymph node metastases (Figures S1A and
S1B available online), suggesting Twist1 is activated in the
primary tumor but not distant metastases. To study how
dynamic activation of Twist1 directly impacts carcinoma
progression, we generated skin-specific Twist1 Tet-on inducible
mice by crossing transgenic mice carrying a single copy of a
TetOP-Twist1 transgene with Keratin 5 promoter-driven reverse
tetracycline-controlled transactivator mice (K5-rtTA) (Diamond
et al., 2000). Bitransgenic mice (referred to as K5-Twist1 mice)
showed specific expression of Twist1 protein in the basal
epidermal layer upon doxycycline (dox) treatment (Figure S1C).
Long-term induction of Twist1 alone in K5-Twist1 mice did not
result in visible skin abnormalities (data not shown). To generate
squamous cell carcinoma (SCC), K5-Twist1 mice and control
single transgene littermates were treated with a single dose of
7,12-dimethylbenz[a]anthracene (DMBA) followed by weekly
applications of 12-O-tetradecanoylphorbol-13-acetate (TPA)
for 20 weeks to allow skin tumor development (Abel et al.,
2009; Kemp, 2005; Sun et al., 2007) (Figure 1A). At the end of
TPA treatment, when all mice have developed multiple papil-
lomas, we randomly divided these mice into two groups. One
group of mice received doxycycline in the drinking water to allow
continuous Twist1 expression in K5-positive tumor cells, even if
tumor cells have migrated out of the skin and disseminated
throughout the body. We used this systemic Twist1 induction
group as the model for ‘‘irreversible EMT.’’ The second group
of mice received doxycycline topically on the dorsal skin area
containing papillomas to induce Twist1 only at the primary tumor
site, such that tumor cells would lose Twist1 expression once
they have disseminated from the skin. This local induction of
Twist1 was used as the model for ‘‘reversible EMT’’ (Figures
1A and S1D).
Within 7 days of doxycycline treatment through either oral or
topical routes, papillomas on the K5-Twist1 mice began to
invaginate into the skin and converted to SCCs at similar rates
in both groups (Figures 1B and 1C). By three weeks, both groups
of K5-Twist1 mice presented over 3-fold higher conversion
frequencies than their control littermates (Figure 1C). Impor-
tantly, induction of Twist1 by oral or topical doxycycline resulted
in similar conversion rates and frequencies of papillomas to
SCCs (52% for oral treatment versus 40% for topical treatment;
Figures 1C and 1D), demonstrating similar efficacy of Twist1
induction at the primary site using both doxycycline delivery
methods. Histological analysis confirmed that papillomas have
converted to poorly differentiated SCCs, with many regions pre-
senting a spindle-cell phenotype in both groups of K5-Twist1
mice, while the naturally converted SCCs in the control group
showed a well- to moderately differentiated epithelial mor-
phology (Figure 1E). In Twist1-induced SCCs, tumor cells
invaded through the underlying basement membrane, demon-
strating a role of Twist1 in matrix degradation (Figure 1F).
Together, these data indicate that Twist1 is sufficient to promote
invasive carcinoma progression in vivo.
Reversible Induction of Twist1 Promotes Carcinoma
To understand how irreversible versus reversible induction of
Twist1 impacts metastasis, we examined individual mice for
distant metastases by macroscopic and histological analysis.
Starting at 5 weeks after doxycycline induction, mice with heavy
metastasis burden were sacrificed together with mice in the
comparison groups, and all mice were terminated by 8 weeks.
Reversibility of EMT Is Essential for Metastasis
726 Cancer Cell 22, 725–736, December 11, 2012 ª2012 Elsevier Inc.
Human Breast Cancer Tissue Microarray
Tissue microarray (TMA) of 99 human breast carcinoma and matched metas-
taseswerepurchased fromUSBiomax Inc.TheTMA contained humantissues
obtained with informed consent according to US federal law and are exempt
from Institutional Review Board review by the University of California, San
Diego Human ResearchProtections Program. Staining for Twist1 and cytoker-
atin was performed as described above. All samples were analyzed for Twist1
expression, and patient samples were considered positive for Twist1 expres-
sion only if >10% of tumor cells in the primary tumor stained positive for
nuclear Twist1. Out of 99 matched samples, only 20 samples met our criteria
forbeing positive forTwist1.Cellswerecountedusingthecell counterfunction
in Image J software.
Statistical analysis was performed using GraphPad Prism Software (La Jolla,
CA). Student’s t test was applied for comparisons between two groups. The
Fisher’s exact test was applied to analyzethe metastasis frequency and tumor
cell extravasation rate using a contingency table. The one-tailed exact bino-
mial test was performed for statistical analysis of Twist1 expression in human
breast cancer TMA.
Supplemental Information includes four figures and can be found with this
article online at http://dx.doi.org/10.1016/j.ccr.2012.09.022.
We thank Konrad Hochedlinger, Colin Jamora, Caroline Beard, Edward
Vizcarra, Ferenc Reinhardt, Esmeralda Casas, Naoto Yoshizuka, and Monique
Aumailley for reagents and invaluable technical help. We thank Robert
Weinberg for his initial support on this work, members of the Yang lab for help-
ful discussions, and Sylvia Evans and Ittai Ben-Porath for critically reading the
manuscript. We thank the Shared Microscope Facility and UCSD Cancer
Center Specialized Support Grant P30 CA23100. This work was supported
by grants from American Cancer Society (RSG-09-282-01-CSM), NIH (DP2
OD002420-01), the Sidney Kimmel Foundation for Cancer Research, and the
University of California Cancer Research Coordinating Committee to J.Y.
J.H.T. was supported by NIH (T32CA121938) and the California Breast Cancer
Program postdoctoral fellowship (16FB-0009).
Received: May 15, 2012
Revised: July 25, 2012
Accepted: September 14, 2012
Published online: November 29, 2012
Abel, E.L., Angel, J.M., Kiguchi, K., and DiGiovanni, J. (2009). Multi-stage
chemical carcinogenesis in mouse skin: fundamentals and applications. Nat.
Protoc. 4, 1350–1362.
Batlle, E., Sancho, E., Francı ´, C., Domı ´nguez, D., Monfar, M., Baulida, J., and
Garcı ´a De Herreros, A. (2000). The transcription factor snail is a repressor of
E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2,
Beard, C., Hochedlinger, K., Plath, K., Wutz, A., and Jaenisch, R. (2006).
Efficient method to generate single-copy transgenic mice by site-specific
integration in embryonic stem cells. Genesis 44, 23–28.
Bierie, B., and Moses, H.L. (2006). Tumour microenvironment: TGFbeta: the
molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6, 506–520.
Blick, T., Widodo, E., Hugo, H., Waltham, M., Lenburg, M.E., Neve, R.M., and
Thompson, E.W. (2008). Epithelial mesenchymal transition traits in human
breast cancer cell lines. Clin. Exp. Metastasis 25, 629–642.
Cameron, M.D., Schmidt, E.E., Kerkvliet, N., Nadkarni, K.V., Morris, V.L.,
Groom, A.C., Chambers, A.F., and MacDonald, I.C. (2000). Temporal progres-
sionofmetastasisinlung:cell survival, dormancy, and location dependence of
metastatic inefficiency. Cancer Res. 60, 2541–2546.
Cano, A., Pe ´rez-Moreno, M.A., Rodrigo, I., Locascio, A., Blanco, M.J., del
Barrio, M.G., Portillo, F., and Nieto, M.A. (2000). The transcription factor snail
controls epithelial-mesenchymal transitions by repressing E-cadherin expres-
sion. Nat. Cell Biol. 2, 76–83.
Celia `-Terrassa, T., Meca-Corte ´s, O´., Mateo, F., de Paz, A.M., Rubio, N., Arnal-
Estape ´, A., Ell, B.J., Bermudo, R., Dı ´az, A., Guerra-Rebollo, M., et al. (2012).
Epithelial-mesenchymal transition can suppress major attributes of human
epithelial tumor-initiating cells. J. Clin. Invest. 122, 1849–1868.
Chambers, A.F., Groom, A.C., and MacDonald, I.C. (2002). Dissemination and
growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563–572.
Chao, Y.L., Shepard, C.R., and Wells, A. (2010). Breast carcinoma cells
re-express E-cadherin during mesenchymal to epithelial reverting transition.
Mol. Cancer 9, 179.
Comijn, J., Berx, G., Vermassen, P., Verschueren, K., van Grunsven, L.,
Bruyneel, E., Mareel, M., Huylebroeck, D., and van Roy, F. (2001). The two-
handed E box binding zinc finger protein SIP1 downregulates E-cadherin
and induces invasion. Mol. Cell 7, 1267–1278.
Diamond, I., Owolabi, T., Marco, M., Lam, C., and Glick, A. (2000). Conditional
gene expression in the epidermis of transgenic mice using the tetracycline-
regulated transactivators tTA and rTA linked to the keratin 5 promoter.
J. Invest. Dermatol. 115, 788–794.
DiGiovanni, J. (1992). Multistage carcinogenesis in mouse skin. Pharmacol.
Ther. 54, 63–128.
Eckert, M.A., Lwin, T.M., Chang, A.T., Kim, J., Danis, E., Ohno-Machado, L.,
and Yang, J. (2011). Twist1-induced invadopodia formation promotes tumor
metastasis. Cancer Cell 19, 372–386.
Eger, A., Aigner, K., Sonderegger, S., Dampier, B., Oehler, S., Schreiber, M.,
Berx, G., Cano, A., Beug, H., and Foisner, R. (2005). DeltaEF1 is a transcrip-
tional repressor of E-cadherin and regulates epithelial plasticity in breast
cancer cells. Oncogene 24, 2375–2385.
Evdokimova,V.,Tognon, C., Ng, T.,Ruzanov,P.,Melnyk,N., Fink,D., Sorokin,
A., Ovchinnikov, L.P., Davicioni, E., Triche, T.J., and Sorensen, P.H. (2009).
Translational activation of snail1 and other developmentally regulated tran-
scription factors by YB-1 promotes an epithelial-mesenchymal transition.
Cancer Cell 15, 402–415.
Wagner, P., Vahdat, L.T., et al. (2012). Myeloid progenitor cells in the preme-
tastatic lung promote metastases by inducing mesenchymal to epithelial
transition. Cancer Res. 72, 1384–1394.
Garber, K. (2008). Epithelial-to-mesenchymal transition is important to metas-
tasis, but questions remain. J. Natl. Cancer Inst. 100, 232–233, 239.
Goss, P.E., and Chambers, A.F. (2010). Does tumour dormancy offer a thera-
peutic target? Nat. Rev. Cancer 10, 871–877.
Goswami, S., Wang, W., Wyckoff, J.B., and Condeelis, J.S. (2004). Breast
cancer cells isolated by chemotaxis from primary tumors show increased
survival and resistance to chemotherapy. Cancer Res. 64, 7664–7667.
Hajra, K.M., Chen, D.Y., and Fearon, E.R. (2002). The SLUG zinc-finger protein
represses E-cadherin in breast cancer. Cancer Res. 62, 1613–1618.
Han, G., Lu, S.L., Li, A.G., He, W., Corless, C.L., Kulesz-Martin, M., and
Wang, X.J. (2005). Distinct mechanisms of TGF-beta1-mediated epithelial-
to-mesenchymal transition and metastasis during skin carcinogenesis.
J. Clin. Invest. 115, 1714–1723.
Hay, E.D. (1995). An overview of epithelio-mesenchymal transformation. Acta
Anat. (Basel) 154, 8–20.
Hou, J.M., Krebs, M., Ward, T., Sloane, R., Priest, L., Hughes, A., Clack, G.,
Ranson, M., Blackhall, F., and Dive, C. (2011). Circulating tumor cells as
a window on metastasis biology in lung cancer. Am. J. Pathol. 178, 989–996.
Hudson, L.G., Zeineldin, R., and Stack, M.S. (2008). Phenotypic plasticity of
neoplastic ovarian epithelium: unique cadherin profiles in tumor progression.
Clin. Exp. Metastasis 25, 643–655.
Hugo, H., Ackland, M.L., Blick, T., Lawrence, M.G., Clements, J.A., Williams,
E.D., and Thompson, E.W. (2007). Epithelial—mesenchymal and mesen-
chymal—epithelial transitions in carcinoma progression. J. Cell. Physiol.
Reversibility of EMT Is Essential for Metastasis
Cancer Cell 22, 725–736, December 11, 2012 ª2012 Elsevier Inc. 735
Hu ¨semann, Y., Geigl, J.B., Schubert, F., Musiani, P., Meyer, M., Burghart, E.,
Forni, G., Eils, R., Fehm, T., Riethmu ¨ller, G., and Klein, C.A. (2008). Systemic
spread is an early step in breast cancer. Cancer Cell 13, 58–68.
Jatana, K.R., Balasubramanian, P., Lang, J.C., Yang, L., Jatana, C.A., White,
E., Agrawal, A., Ozer, E., Schuller, D.E., Teknos, T.N., and Chalmers, J.J.
(2010). Significance of circulating tumor cells in patients with squamous cell
carcinoma of the head and neck: initial results. Arch. Otolaryngol. Head
Neck Surg. 136, 1274–1279.
Kallergi, G., Papadaki, M.A., Politaki, E., Mavroudis, D., Georgoulias, V., and
Agelaki, S. (2011). Epithelial to mesenchymal transition markers expressed
in circulating tumour cells of early and metastatic breast cancer patients.
Breast Cancer Res. 13, R59.
Kalluri, R., and Weinberg, R.A. (2009). The basics of epithelial-mesenchymal
transition. J. Clin. Invest. 119, 1420–1428.
Kemp, C.J. (2005). Multistep skin cancer in mice as a model to study the
evolution of cancer cells. Semin. Cancer Biol. 15, 460–473.
Ledford, H. (2011). Cancer theory faces doubts. Nature 472, 273.
Luzzi, K.J., MacDonald, I.C., Schmidt, E.E., Kerkvliet, N., Morris, V.L.,
Chambers, A.F., and Groom, A.C. (1998). Multistep nature of metastatic inef-
ficiency: dormancy of solitary cells after successful extravasation and limited
survival of early micrometastases. Am. J. Pathol. 153, 865–873.
Mani, S.A., Yang, J., Brooks, M., Schwaninger, G., Zhou, A., Miura, N., Kutok,
J.L., Hartwell, K., Richardson, A.L., and Weinberg, R.A. (2007). Mesenchyme
Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with
aggressive basal-like breast cancers. Proc. Natl. Acad. Sci. USA 104,
Mendoza, A., Hong, S.H., Osborne, T., Khan, M.A., Campbell, K., Briggs, J.,
Eleswarapu,A.,Buquo, L.,Ren,L.,Hewitt,S.M.,etal.(2010).Modeling metas-
tasis biology and therapy in real time in the mouse lung. J. Clin. Invest. 120,
Meng, S., Tripathy, D., Frenkel, E.P., Shete, S., Naftalis, E.Z., Huth, J.F.,
Beitsch, P.D., Leitch, M., Hoover, S., Euhus, D., et al. (2004). Circulating tumor
cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152–
Min, A.L., Choi, J.Y., Woo, H.Y., Kim, J.D., Kwon, J.H., Bae, S.H., Yoon, S.K.,
Shin, S.H., Chung, Y.J., and Jung, C.K. (2009). High expression of Snail mRNA
in blood from hepatocellular carcinoma patients with extra-hepatic metas-
tasis. Clin. Exp. Metastasis 26, 759–767.
Ou, D.L., Chien, H.F., Chen, C.L., Lin, T.C., and Lin, L.I. (2008). Role of Twist in
head and neck carcinoma with lymph node metastasis. Anticancer Res. 28
Pajonk, F., Schlessmann, S., Guttenberger, R., and Henke, M. (2001).
Epithelial cells in the peripheral blood of patients with cancer of the head
and neck: incidence, detection and possible clinical significance. Radiother.
Oncol. 59, 213–217.
Peinado, H., Olmeda, D., and Cano, A. (2007). Snail, Zeb and bHLH factors in
tumour progression: an alliance against the epithelial phenotype? Nat. Rev.
Cancer 7, 415–428.
Perez-Losada, J., and Balmain, A. (2003). Stem-cell hierarchy in skin cancer.
Nat. Rev. Cancer 3, 434–443.
Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F.,
Reichert, M., Beatty, G.L., Rustgi, A.K., Vonderheide, R.H., et al. (2012).
EMT and dissemination precede pancreatic tumor formation. Cell 148,
Sasaki, K., Natsugoe, S., Ishigami, S., Matsumoto, M., Okumura, H.,
Setoyama, T., Uchikado, Y., Kita, Y., Tamotsu, K., Sakamoto, A., et al.
(2009). Significance of Twist expression and its association with E-cadherin
in esophageal squamous cell carcinoma. J. Exp. Clin. Cancer Res. 28, 158.
Sugarbaker, P.H. (1993). Metastatic inefficiency: the scientific basis for resec-
tion of liver metastases from colorectal cancer. J. Surg. Oncol. Suppl. 3,
Sun, P., Yoshizuka, N., New, L., Moser, B.A., Li, Y., Liao, R., Xie, C., Chen, J.,
Deng, Q., Yamout, M., et al. (2007). PRAK is essential for ras-induced senes-
cence and tumor suppression. Cell 128, 295–308.
Tarin, D., Thompson, E.W., and Newgreen, D.F. (2005). The fallacy of epithelial
mesenchymal transition in neoplasia. Cancer Res. 65, 5996–6000.
Thiery, J.P. (2002). Epithelial-mesenchymal transitions in tumour progression.
Nat. Rev. Cancer 2, 442–454.
Thiery, J.P., Acloque, H., Huang, R.Y., and Nieto, M.A. (2009). Epithelial-
mesenchymal transitions in development and disease. Cell 139, 871–890.
Thompson, E.W., Newgreen, D.F., and Tarin, D. (2005). Carcinoma invasion
and metastasis: a role for epithelial-mesenchymal transition? Cancer Res.
65, 5991–5995, discussion 5995.
Tsuji, T., Ibaragi, S., Shima, K., Hu, M.G., Katsurano, M., Sasaki, A., and Hu,
G.F. (2008). Epithelial-mesenchymal transition induced by growth suppressor
p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant
colony growth. Cancer Res. 68, 10377–10386.
Vega, S., Morales, A.V., Ocan ˜a, O.H., Valde ´s, F., Fabregat, I., and Nieto, M.A.
(2004). Snail blocks the cell cycle and confers resistance to cell death. Genes
Dev. 18, 1131–1143.
Wang, W., Goswami, S., Lapidus, K., Wells, A.L., Wyckoff, J.B., Sahai, E.,
Singer, R.H., Segall, J.E., and Condeelis, J.S. (2004). Identification and testing
of a gene expression signature of invasive carcinoma cells within primary
mammary tumors. Cancer Res. 64, 8585–8594.
Watson, M.A., Ylagan, L.R., Trinkaus, K.M., Gillanders, W.E., Naughton, M.J.,
Weilbaecher, K.N., Fleming, T.P., and Aft, R.L. (2007). Isolation and molecular
profiling of bone marrow micrometastases identifies TWIST1 as a marker of
early tumor relapse in breast cancer patients. Clin. Cancer Res. 13, 5001–
Weeks, B.H., He, W., Olson, K.L., and Wang, X.J. (2001). Inducible expression
of transforming growth factor beta1 in papillomas causes rapid metastasis.
Cancer Res. 61, 7435–7443.
Weiss, L. (1990). Metastatic inefficiency. Adv. Cancer Res. 54, 159–211.
Winter, S.C., Stephenson, S.A., Subramaniam, S.K., Paleri, V., Ha, K.,
Marnane, C., Krishnan, S., and Rees, G. (2009). Long term survival following
thedetection of circulating tumourcells inhead and neck squamous cell carci-
noma. BMC Cancer 9, 424.
Wushou, A., Pan, H.Y., Liu, W., Tian, Z., Wang, L.Z., Shali, S., and Zhang, Z.Y.
(2012). Correlation of increased twist with lymph node metastasis in patients
with oral squamous cell carcinoma. J. Oral Maxillofac. Surg. 70, 1473–1479.
Xie, F., Li, K., and Ouyang, X. (2009). Twist, an independent prognostic marker
for predicting distant metastasis and survival rates of esophageal squamous
cell carcinoma patients. Clin. Exp. Metastasis 26, 1025–1032.
Yang, J., Mani, S.A., Donaher, J.L., Ramaswamy, S., Itzykson, R.A., Come, C.,
Savagner, P., Gitelman, I., Richardson, A., and Weinberg, R.A. (2004). Twist,
a master regulator of morphogenesis, plays an essential role in tumor metas-
tasis. Cell 117, 927–939.
Yuen, H.F., Chan, Y.P., Wong, M.L., Kwok, W.K., Chan, K.K., Lee, P.Y.,
Srivastava, G., Law, S.Y., Wong, Y.C., Wang, X., and Chan, K.W. (2007).
Upregulation of Twist in oesophageal squamous cell carcinoma is associated
with neoplastic transformation and distant metastasis. J. Clin. Pathol. 60,
Reversibility of EMT Is Essential for Metastasis
736 Cancer Cell 22, 725–736, December 11, 2012 ª2012 Elsevier Inc.